Mark Daly, Ph.D. is the Director of the Institute of Molecular Medicine Finland FIMM, where he succeeds Academy Professor Jaakko Kaprio as of February 1, 2018.  Mark was recruited from Harvard Medical School – where he was the founding chief of the Analytic and Translational Unit at the Massachusetts General Hospital from 2011 - and the Broad Institute of MIT and Harvard.

While primarily based in Finland, he retains an active role in Boston at HMS/MGH and as an Institute Member at the Broad Institute, where he is establishing a close partnership between FIMM and the Broad Institute.

Mark’s primary research focus is discovery of genes involved in human disease as a means of providing both insights for therapeutic development as well as improved diagnostics for individual patients.  His lab has developed many foundational computational tools and statistical techniques in genome mapping, linkage and association, and automated interpretation of laboratory data.  The lab has a significant and longstanding commitment in two major medical areas: the inflammatory bowel diseases (Crohn’s and ulcerative colitis) and neuropsychiatric disease (autism and schizophrenia) and Mark has led international consortium efforts large-scale gene mapping efforts in each of these areas – co-chairing the International IBD Genetics Consortium (https://www.ibdgenetics.org), the Psychiatric Genomics Consortium (pgc.unc.edu) and the Autism Sequencing Consortium. With Dr. Palotie, he has helped design and launch the FinnGen Project (www.finngen.fi) as a transformative public-private partnership.  Mark Daly has been an author on more than 450 peer-reviewed manuscripts with a total of more than 200,000 citations, has an h-index of 178, and has been listed by Thompson ISI/Science Watch in 2008 and 2010 as one of the top ten authors ranked by number of high-impact papers.  Mark was the recipient of the Curt Stern Award from the American Society of Human Genetics in 2014 and was elected to the National Academy of Medicine in 2017.